# A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

> **NCT06568692** · PHASE2 · RECRUITING · sponsor: **Processa Pharmaceuticals** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- HER2-negative Breast Cancer

## Interventions

- **DRUG:** PCS6422 and capecitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06568692
- **Lead sponsor:** Processa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2026-09
- **Final completion:** 2026-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06568692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06568692, "A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06568692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*